KAZAN, Russian Federation, March 31 /PRNewswire/ - Neuro-Biotech Corp. (PinkSheets: MRES) (OTCQB: MRES) announces that following the resumption of the buyout offer at $0.15 by AURIC Pharma Science, the Company will proceed to the closing session on Tuesday April 5 at its new corporate head office in Kazan, Russian Federation.
Mr. Boris Oleknovich, the Company new CEO and President commented: "We figured this would be a perfect opportunity for the people at AURIC and our shareholders to come and visit the new Neuro-Biotech head office as well as get to know the new team steering the ship"
Neuro-Biotech Corp. filed and 8K to this effect with the details about the new CEO and President Mr Boris Oleknovich as well as the address of the new head office.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.